Richard Kane, MIPP, MA, and Josh Seidman, PhD, MHS, both with Avalere Health, share their thoughts on the intricacies of the MACRA Merit-Based Incentive Payment System and the risk practices must accept when transitioning to the Oncology Care Model.
Ray D Page, DO, PhD, addresses how including drug costs in bundled payments places oncology practices at the uncontrollable probabilistic risk of patient case mixes.
Many physicians still mistakenly believe that hospice and palliative medicine are one and the same, according to Timothy W Holder, MD, medical director, supportive care and survivorship, Cancer Treatment Centers of America.
Referral of newly diagnosed adolescent patients with acute lymphoblastic leukemia to pediatric and National Cancer Institute-designated centers should be strongly recommended.
Robert M Rifkin, MD, FACP, gave an update on the basics, education, and reimbursement of biosimilars, stating that “this will be a huge year” for the the copycat biologics in the United States.
A recent study compared the costs and toxicities of proton radiation, stereotactic body radiotherapy, and intensity-modulated radiotherapy for younger patients with prostate cancer.
Younger patients who received certain chemotherapies for solid tumors or leukemia may not have T-cells capable of becoming effective CAR T-cells.
A recent study investigated whether risk-standardized mortality rate is an effective predictor of long-term survival in hospitalized patients with heart failure.
Results of a large study supported by the National Cancer Institute found that patients who survived testicular cancer are at a higher risk of developing heart disease.
Treatment with a BTK inhibitor has been shown to yield good depth and duration of response in patients with chronic lymphocytic leukemia, regardless of TP53 status.